Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J, Roché H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavère P, Barats JC, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I. Bonneterre J, et al. Among authors: fumoleau p. J Clin Oncol. 2004 Aug 1;22(15):3070-9. doi: 10.1200/JCO.2004.03.098. J Clin Oncol. 2004. PMID: 15284257 Clinical Trial.
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.
Diéras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, Guastalla JP, Pujade-Lauraine E, Kerbrat P, Maillart P, Pénault-Llorca F, Buyse M, Pouillart P. Diéras V, et al. Among authors: fumoleau p. J Clin Oncol. 2004 Dec 15;22(24):4958-65. doi: 10.1200/JCO.2004.02.122. J Clin Oncol. 2004. PMID: 15611510 Clinical Trial.
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
Bonneterre J, Roché H, Kerbrat P, Brémond A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P, Chapelle-Marcillac I. Bonneterre J, et al. Among authors: fumoleau p. J Clin Oncol. 2005 Apr 20;23(12):2686-93. doi: 10.1200/JCO.2005.05.059. J Clin Oncol. 2005. PMID: 15837983 Clinical Trial.
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B. Roché H, et al. Among authors: fumoleau p. J Clin Oncol. 2006 Dec 20;24(36):5664-71. doi: 10.1200/JCO.2006.07.3916. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116941 Clinical Trial.
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M. Chevallier B, et al. Among authors: fumoleau p. J Clin Oncol. 1995 Feb;13(2):314-22. doi: 10.1200/JCO.1995.13.2.314. J Clin Oncol. 1995. PMID: 7844592 Clinical Trial.
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P. Dieras V, et al. Among authors: fumoleau p. Br J Cancer. 1996 Aug;74(4):650-6. doi: 10.1038/bjc.1996.416. Br J Cancer. 1996. PMID: 8761385 Free PMC article. Clinical Trial.
280 results